(2-nitrophenyl)(thiophen-2-yl)methanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-nitrophenyl)(thiophen-2-yl)methanol
• 英文别名: (2-Nitrophenyl)-thiophen-2-ylmethanol
• 化学式: C₁₁H₉NO₃S
• 分子量: 235.263
• InChiKey: HOVUVYYNGMWAOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  94.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-nitrophenyl)(thiophen-2-yl)methanol 在 sodium tetrahydroborate 、 nickel(II) chloride hexahydrate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 2.17h， 生成 (2-氨基苯基)-(2-噻吩基)甲醇
  参考文献：
  名称：

  Cascade Synthesis of 3-Quinolinecarboxylic Ester via Benzylation/ Propargylation−Cyclization

  摘要：

  Reactions of 2-amino-aryl alcohols with beta-ketoesters catalyzed by a catalytic amout of FeCl3 via tandem benzylation-cyclization produce the corresponding 3-quinolinecarboxylic esters in good to high yields. Extending this methodology to propargylation-cyclization, 2-nitrophenyl proparoyl alcohols with beta-ketoesters catalyzed by FeCl3 and SnCl, also produce the 4-alkyne-3-quitiolinecarboxylic esters. The mechanistic details of this benzylation/proparoylation and cyclization cascade process are also discussed.

  DOI：

  10.1021/jo8017654
• 作为产物：
  描述：

  (2-nitro-phenyl)-thiophen-2-yl-methanone 在 sodium tetrahydroborate 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 反应 3.5h， 生成 (2-nitrophenyl)(thiophen-2-yl)methanol
  参考文献：
  名称：

  Cascade Synthesis of 3-Quinolinecarboxylic Ester via Benzylation/ Propargylation−Cyclization

  摘要：

  Reactions of 2-amino-aryl alcohols with beta-ketoesters catalyzed by a catalytic amout of FeCl3 via tandem benzylation-cyclization produce the corresponding 3-quinolinecarboxylic esters in good to high yields. Extending this methodology to propargylation-cyclization, 2-nitrophenyl proparoyl alcohols with beta-ketoesters catalyzed by FeCl3 and SnCl, also produce the 4-alkyne-3-quitiolinecarboxylic esters. The mechanistic details of this benzylation/proparoylation and cyclization cascade process are also discussed.

  DOI：

  10.1021/jo8017654

文献信息

• From <i>in vitro</i> to <i>in cellulo</i>: structure–activity relationship of (2-nitrophenyl)methanol derivatives as inhibitors of PqsD in <i>Pseudomonas aeruginosa</i>
  作者：Michael P. Storz、Giuseppe Allegretta、Benjamin Kirsch、Martin Empting、Rolf W. Hartmann

  DOI：10.1039/c4ob00707g

  日期：——

  More than 60 derivatives of (2-nitrophenyl)methanol were synthesized and evaluated regarding their potency to inhibit PqsD. In vitro and in cellulo structure–activity relationships were derived.

  超过60种(2-硝基苯基)甲醇衍生物被合成并评估其抑制PqsD的效力。得出了体外和体内结构-活性关系。
• 2-(substituted-phenyl)amino-imidazoline derivatives
  申请人：——

  公开号：US20030036655A1

  公开（公告）日：2003-02-20

  This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: 1 where: R 1 is a group represented by formula (A), (B) or (C); 2 d other substituents as defined in the specification, and their pharmaceutically acceptable ts or crystal forms thereof; and pharmaceutical compositions containing them; and methods their use as therapeutic agents.

  本发明涉及IP受体拮抗剂，其选自由式I所表示的化合物组中：其中：R1是由式(A)、(B)或(C)表示的基团；2d是根据说明书中定义的其他取代基，以及它们的药学上可接受的盐或晶体形式；以及包含它们的药物组合物；以及将它们用作治疗剂的方法。
• 2-(Substituted-phenyl)amino-imidazoline derivatives
  申请人：——

  公开号：US20030229123A1

  公开（公告）日：2003-12-11

  This invention relates to IP receptor antagonists selected from the group of compounds represented by Formula I: 1 where: R 1 is a group represented by formula (A), (B) or (C); 2 d other substituents as defined in the specification, and their pharmaceutically acceptable ts or crystal forms thereof; and pharmaceutical compositions containing them; and methods their use as therapeutic agents.

  本发明涉及从由公式I所代表的化合物组中选择的IP受体拮抗剂：1其中：R1是由公式（A），（B）或（C）表示的基团；2d是在规范中定义的其他取代基，以及它们的药学上可接受的盐或晶体形式；以及包含它们的药物组合物；以及它们作为治疗剂的使用方法。
• 2-(Arylphenyl)amino-imidazoline derivatives
  申请人：F. HOFFMANN-LA ROCHE AG

  公开号：EP0902018A2

  公开（公告）日：1999-03-17

  The invention relates to IP receptor antagonists selected from the group of compounds represented by formula wherein R1 is a group represented by formula (A), (B) or (C): and other substituents as defined in the specification, and their pharmaceutically acceptable salts, crystal forms therof and pharmaceutical compositions containing them.

  本发明涉及 IP 受体拮抗剂，这些受体选自由式表示的化合物组。 式中 R1为式(A)、(B)或(C)所代表的基团： 和说明书中定义的其它取代基的化合物，以及它们的药学上可接受的盐、它们的晶体形式和含有它们的药物组合物。
• US6184242B1
  申请人：——

  公开号：US6184242B1

  公开（公告）日：2001-02-06